Biogen’s Japanese Partner Has a Second Alzheimer’s Drug Coming

bloomberg2021-06-08

Biogen Inc. beat the odds, bringing the first drug intended to slow the progression of Alzheimer’s disease to the U.S market. Investors are hoping Eisai Co. Ltd, its Japanese partner in the medicine, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

McGreedy
2021-06-08
McGreedy
Like and comment pls
- Derrick0359:
  Ok
BBBBBBBBBB
2021-06-08
BBBBBBBBBB
Like n comment pls
lost0star
2021-06-08
lost0star
Okay
- lost0star:
  okay
alvernsim
2021-06-08
alvernsim
Like and comment pls!
- alvernsim:
  Thanks!
- alvernsim:
  Thanks!
- Shinshinc:
  like commented. reply back ty?
我已经戒赌股票了相信我
2021-06-08
我已经戒赌股票了相信我
Ok
- 我已经戒赌股票了相信我:
  ic
- Mxxww:
  Yes
- Shinshinc:
  do it
michiec
2021-06-08
michiec
Please like and comment
- 雨天不撑伞:
  Please reply back
- 雨天不撑伞:
  Done

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135714831?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-08 14:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135714831","market":"us","top_or_hot":-1,"title":"Biogen’s Japanese Partner Has a Second Alzheimer’s Drug Coming","media":"bloomberg","content":"<div>\n<p>Biogen Inc. beat the odds, bringing the first drug intended to slow the progression of Alzheimer’s disease to the U.S market. Investors are hoping Eisai Co. Ltd, its Japanese partner in the medicine, ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-08/biogen-s-alzheimer-drug-nod-may-bode-well-for-eisai-s-efforts\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen’s Japanese Partner Has a Second Alzheimer’s Drug Coming</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen’s Japanese Partner Has a Second Alzheimer’s Drug Coming\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 14:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-08/biogen-s-alzheimer-drug-nod-may-bode-well-for-eisai-s-efforts><strong>bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc. beat the odds, bringing the first drug intended to slow the progression of Alzheimer’s disease to the U.S market. Investors are hoping Eisai Co. Ltd, its Japanese partner in the medicine, ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-08/biogen-s-alzheimer-drug-nod-may-bode-well-for-eisai-s-efforts\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2021-06-08/biogen-s-alzheimer-drug-nod-may-bode-well-for-eisai-s-efforts","article_id":"1135714831","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135714831","pubTimestamp":1623135005,"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"Biogen Inc. beat the odds, bringing the first drug intended to slow the progression of Alzheimer’s d","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"生化基因的日本伴侣有第二种老年痴呆症药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":0.9},"content_text":"Biogen Inc. beat the odds, bringing the first drug intended to slow the progression of Alzheimer’s disease to the U.S market. Investors are hoping Eisai Co. Ltd, its Japanese partner in the medicine, can do it again with a second compound from the pair that’s still in development.The U.S. Food and Drug Administration’s backing of the drug Aduhelm may boost the chances for BAN2401 and Tokyo-based Eisai, which is in a sales and profit sharing agreement with Biogen for both treatments. The drugs work by targeting the beta amyloid protein that clogs the brains of patients with Alzheimer’s disease.Researchers long believed that interfering with the protein, a hallmark of the disease, was the key to treating the condition, but pharmaceutical companies spent billions of dollars on experimental compounds that failed again and again to slow the inexorable progression of the mind-wasting disease. Aduhelm is the first such medicine to make it to the market.“This approval will have a halo effect on BAN2401 and the wider pipeline,” said Jefferies analyst Stephen Barker. “It will certainly impact how the stock market evaluates the Alzheimer’s research from Biogen and Eisai in general.”The Japanese drugmaker partnered with Biogenin 2014to co-develop several Alzheimer’s related compounds. In 2017, Eisai exercised an option toexpand the agreementEisai’s shares were untraded in Tokyo Tuesday amid a trading imbalance, as bids outweighed offers. Biogen shares closed at $395.85, up 38.3% in U.S. trading.Two TrialsEisai is leading two pivotal trials on BAN2401, which also goes by the name lecanemab. Final results for the study in patients with early-stage disease are expected within the next year. The FDA’s approval of Aduhelm may indicate a shift in how the agency thinks about Alzheimer’s disease, and the sentiments are lifting expectations for the experimental compound’s future.“Our other drug lecanemab is also based on the beta amyloid hypothesis, so we are very encouraged by this approval,” an Eisai spokesman told Bloomberg by phone.Closer on the calendar are regulatory approval decisions for Aduhelm in Europe and Japan, which will likely come later this year, Barker said.Japan’s top government spokesman Katsunobu Kato said Tuesday that the country would review the drug in an appropriate manner, while Australia’s Therapeutic Goods Administration said it is currently evaluating the medication.For the Aduhelm agreement, Eisai will book sales in Asia outside of China and South Korea, while Biogen will book most of the rest of the world, including U.S. and Europe.Profits will be split about 50-50, with Biogen taking a greater share in U.S. and Europe, and Eisai taking a greater share in Japan and Asia, other than China and South Korea.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":117636201,"gmtCreate":1623136315503,"gmtModify":1704196805474,"author":{"id":"3560280328484327","authorId":"3560280328484327","name":"McGreedy","avatar":"https://static.tigerbbs.com/96af4bcc46326043bb64926e01f6724c","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":1,"crmLevelSwitch":1,"idStr":"3560280328484327","authorIdStr":"3560280328484327"},"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/117636201","repostId":1135714831,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4630154,"gmtCreate":1623136941854,"gmtModify":1663228187239,"authorId":3574151642706297,"author":{"id":3574151642706297,"idStr":"3574151642706297","authorId":3574151642706297,"name":"Derrick0359","avatar":"https://static.tigerbbs.com/1e4377b13ebe2fd65f630bf249fd6624","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":117636201,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":117636030,"gmtCreate":1623136220620,"gmtModify":1704196805140,"author":{"id":"3581562365927542","authorId":"3581562365927542","name":"BBBBBBBBBB","avatar":"https://static.tigerbbs.com/973395458d7e1db24dbd4a689c79e8a2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581562365927542","authorIdStr":"3581562365927542"},"htmlText":"Like n comment pls&nbsp;","listText":"Like n comment pls&nbsp;","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/117636030","repostId":1135714831,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":117631161,"gmtCreate":1623135992153,"gmtModify":1704196802864,"author":{"id":"3577931905567659","authorId":"3577931905567659","name":"lost0star","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3577931905567659","authorIdStr":"3577931905567659"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/117631161","repostId":1135714831,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4630044,"gmtCreate":1623135999642,"gmtModify":1663228188629,"authorId":3577931905567659,"author":{"id":3577931905567659,"idStr":"3577931905567659","authorId":3577931905567659,"name":"lost0star","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":117631161,"type":1,"supId":0,"prevId":0,"content":"<u>okay</u>","text":"<u>okay</u>","html":"<u>okay</u>"}],"langContent":"EN"},{"id":117633794,"gmtCreate":1623135962918,"gmtModify":1704196802052,"author":{"id":"3575936957429593","authorId":"3575936957429593","name":"alvernsim","avatar":"https://static.tigerbbs.com/c2fe3d62fe9cea4c6c6e6417f045322d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3575936957429593","authorIdStr":"3575936957429593"},"htmlText":"Like and comment pls!","listText":"Like and comment pls!","text":"Like and comment pls!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/117633794","repostId":1135714831,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4663424,"gmtCreate":1623308113031,"gmtModify":1663228351644,"authorId":3575936957429593,"author":{"id":3575936957429593,"idStr":"3575936957429593","authorId":3575936957429593,"name":"alvernsim","avatar":"https://static.tigerbbs.com/c2fe3d62fe9cea4c6c6e6417f045322d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":117633794,"type":1,"supId":4630041,"prevId":0,"content":"Thanks!","text":"Thanks!","html":"Thanks!"},{"id":4630049,"gmtCreate":1623136020420,"gmtModify":1663228187044,"authorId":3575936957429593,"author":{"id":3575936957429593,"idStr":"3575936957429593","authorId":3575936957429593,"name":"alvernsim","avatar":"https://static.tigerbbs.com/c2fe3d62fe9cea4c6c6e6417f045322d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":117633794,"type":1,"supId":4630041,"prevId":0,"content":"Thanks!","text":"Thanks!","html":"Thanks!"},{"id":4630041,"gmtCreate":1623135984542,"gmtModify":1663228186242,"authorId":3584697624877811,"author":{"id":3584697624877811,"idStr":"3584697624877811","authorId":3584697624877811,"name":"Shinshinc","avatar":"https://static.tigerbbs.com/98e6d35ddaae02c25196a93f23dd3903","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":117633794,"type":1,"supId":0,"prevId":0,"content":"like commented. reply back ty?","text":"like commented. reply back ty?","html":"like commented. reply back ty?"}],"langContent":"EN"},{"id":117633624,"gmtCreate":1623135940368,"gmtModify":1704196801725,"author":{"id":"3571736667951592","authorId":"3571736667951592","name":"我已经戒赌股票了相信我","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3571736667951592","authorIdStr":"3571736667951592"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/117633624","repostId":1135714831,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4655553,"gmtCreate":1623279583919,"gmtModify":1663228311844,"authorId":3571736667951592,"author":{"id":3571736667951592,"idStr":"3571736667951592","authorId":3571736667951592,"name":"我已经戒赌股票了相信我","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":117633624,"type":1,"supId":4630067,"prevId":0,"content":"<u>ic</u>","text":"<u>ic</u>","html":"<u>ic</u>"},{"id":4630067,"gmtCreate":1623136188850,"gmtModify":1663228187436,"authorId":3555242813505063,"author":{"id":3555242813505063,"idStr":"3555242813505063","authorId":3555242813505063,"name":"Mxxww","avatar":"https://community-static.tradeup.com/news/e5f0b361a6feb4586a0645c00af5bfaa","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.12","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":117633624,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"},{"id":4630042,"gmtCreate":1623135991385,"gmtModify":1663228187338,"authorId":3584697624877811,"author":{"id":3584697624877811,"idStr":"3584697624877811","authorId":3584697624877811,"name":"Shinshinc","avatar":"https://static.tigerbbs.com/98e6d35ddaae02c25196a93f23dd3903","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":117633624,"type":1,"supId":0,"prevId":0,"content":"do it","text":"do it","html":"do it"}],"langContent":"EN"},{"id":117695441,"gmtCreate":1623135555883,"gmtModify":1704196796005,"author":{"id":"3576840215575990","authorId":"3576840215575990","name":"michiec","avatar":"https://static.tigerbbs.com/a4ab42a03acfbe58db7e84b49daf9682","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576840215575990","authorIdStr":"3576840215575990"},"htmlText":"Please like and comment","listText":"Please like and comment","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/117695441","repostId":1135714831,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4630010,"gmtCreate":1623135763976,"gmtModify":1663228188442,"authorId":3581720011615234,"author":{"id":3581720011615234,"idStr":"3581720011615234","authorId":3581720011615234,"name":"雨天不撑伞","avatar":"https://static.tigerbbs.com/8722060ea3af0a91b655bd116ce76ae5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":117695441,"type":1,"supId":4629999,"prevId":0,"content":"Please reply back","text":"Please reply back","html":"Please reply back"},{"id":4629999,"gmtCreate":1623135688348,"gmtModify":1663228187626,"authorId":3581720011615234,"author":{"id":3581720011615234,"idStr":"3581720011615234","authorId":3581720011615234,"name":"雨天不撑伞","avatar":"https://static.tigerbbs.com/8722060ea3af0a91b655bd116ce76ae5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":117695441,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":21,"commentSize":13,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135714831"}